159 related articles for article (PubMed ID: 37243801)
1. Impact of rituximab on humoral response to SARS-CoV-2 vaccination in previously vaccinated patients with autoimmune diseases.
Oliosi E; Flahault A; Charre C; Veyer D; Combier A; Lafont E; Karras A; Mouthon L; Avouac J; Terrier B; Hadjadj J
Clin Rheumatol; 2023 Sep; 42(9):2485-2490. PubMed ID: 37243801
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M
Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048
[TBL] [Abstract][Full Text] [Related]
3. Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections.
Egri N; Calderón H; Martinez R; Vazquez M; Gómez-Caverzaschi V; Pascal M; Araújo O; Juan M; González-Navarro EA; Hernández-Rodríguez J
Front Immunol; 2023; 14():1146841. PubMed ID: 37180097
[TBL] [Abstract][Full Text] [Related]
4. Humoral immunogenicity of COVID-19 vaccines in patients with inflammatory rheumatic diseases under treatment with Rituximab: a case-control study (COVID-19VacRTX).
Schumacher F; Mrdenovic N; Scheicht D; Pons-Kühnemann J; Scheibelhut C; Strunk J
Rheumatology (Oxford); 2022 Oct; 61(10):3912-3918. PubMed ID: 35094050
[TBL] [Abstract][Full Text] [Related]
5. Sustained cell-mediated but not humoral responses in rituximab-treated rheumatic patients after vaccination against SARS-CoV-2.
Thomas Κ; Grigoropoulos I; Alexopoulou P; Karofylakis E; Galani I; Papadopoulou KK; Tsiavou A; Ntourou A; Mavrou E; Qevani I; Katsimbri P; Koutsianas C; Mavrea E; Vassilopoulos D; Pournaras S; Tsiodras S; Boumpas D; Antoniadou A
Rheumatology (Oxford); 2024 Feb; 63(2):534-541. PubMed ID: 37228039
[TBL] [Abstract][Full Text] [Related]
6. Immune response to SARS-CoV-2 mRNA vaccination in multiple sclerosis patients after rituximab treatment interruption.
Gröning R; Dernstedt A; Ahlm C; Normark J; Sundström P; Forsell MNE
Front Immunol; 2023; 14():1219560. PubMed ID: 37575257
[TBL] [Abstract][Full Text] [Related]
7. Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab.
Nytrova P; Stastna D; Tesar A; Menkyova I; Posova H; Koprivova H; Mikulova V; Hrdy J; Smela G; Horakova D; Rysankova I; Doleckova K; Tyblova M
Front Immunol; 2023; 14():1149629. PubMed ID: 37398654
[TBL] [Abstract][Full Text] [Related]
8. B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With Rituximab.
Stefanski AL; Rincon-Arevalo H; Schrezenmeier E; Karberg K; Szelinski F; Ritter J; Jahrsdörfer B; Schrezenmeier H; Ludwig C; Sattler A; Kotsch K; Chen Y; Claußnitzer A; Haibel H; Proft F; Guerra G; Durek P; Heinrich F; Ferreira-Gomes M; Burmester GR; Radbruch A; Mashreghi MF; Lino AC; Dörner T
Arthritis Rheumatol; 2022 Jun; 74(6):934-947. PubMed ID: 34962360
[TBL] [Abstract][Full Text] [Related]
9. A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases.
Tzioufas AG; Bakasis AD; Goules AV; Bitzogli K; Cinoku II; Chatzis LG; Argyropoulou OD; Venetsanopoulou AI; Mavrommati M; Stergiou IE; Pezoulas V; Voulgari PV; Katsimpari C; Katechis S; Gazi S; Katsifis G; Sfontouris CI; Georgountzos AI; Liossis SN; Papagoras C; Fotiadis DI; Skopouli FN; Vlachoyiannopoulos PG; Moutsopoulos HM
J Autoimmun; 2021 Dec; 125():102743. PubMed ID: 34757289
[TBL] [Abstract][Full Text] [Related]
10. Rituximab Impairs B Cell Response But Not T Cell Response to COVID-19 Vaccine in Autoimmune Diseases.
Bitoun S; Henry J; Desjardins D; Vauloup-Fellous C; Dib N; Belkhir R; Mouna L; Joly C; Bitu M; Ly B; Pascaud J; Seror R; Roque Afonso AM; Le Grand R; Mariette X
Arthritis Rheumatol; 2022 Jun; 74(6):927-933. PubMed ID: 34962357
[TBL] [Abstract][Full Text] [Related]
11. Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals.
Ogrič M; Žigon P; Podovšovnik E; Lakota K; Sodin-Semrl S; Rotar Ž; Čučnik S
Front Immunol; 2022; 13():876533. PubMed ID: 35711413
[TBL] [Abstract][Full Text] [Related]
12. Risk factors of impaired humoral response to COVID-19 vaccination in rituximab-treated patients.
Avouac J; Miceli-Richard C; Combier A; Steelandt A; Fogel O; Mariaggi AA; Meritet JF; Rozenberg F; Molto A; Allanore Y
Rheumatology (Oxford); 2022 Jun; 61(SI2):SI163-SI168. PubMed ID: 34726701
[TBL] [Abstract][Full Text] [Related]
13. Analysis of factors involved in the development of humoral response to vaccination against SARS-CoV-2 in patients with rheumatic pathology under biological treatment.
Flores-Fernández E; Vázquez-Gomez I; Valls-Pascual E; Valera-Ribera C; Andújar-Brazal P; Alegre-Sancho JJ
Reumatol Clin (Engl Ed); 2023 Dec; 19(10):565-570. PubMed ID: 38008603
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of SARS-CoV-2 vaccination in rituximab-treated patients: Effect of timing and immunologic parameters.
Magliulo D; Wade SD; Kyttaris VC
Clin Immunol; 2022 Jan; 234():108897. PubMed ID: 34848357
[TBL] [Abstract][Full Text] [Related]
15. Rituximab-treated rheumatic patients: B cells predict seroconversion after COVID-19 boost or revaccination in initial vaccine non-responders.
Ammitzbøll C; Kragh Thomsen M; Bøgh Andersen J; Jensen JMB; From Hermansen ML; Dahl Johannsen A; Larsen ML; Mistegaard CE; Mikkelsen S; Szabados F; Vils SR; Erikstrup C; Hauge EM; Troldborg A
Rheumatology (Oxford); 2023 Jul; 62(7):2544-2549. PubMed ID: 36445008
[TBL] [Abstract][Full Text] [Related]
16. High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients.
Fabris M; De Marchi G; Domenis R; Caponnetto F; Guella S; Dal Secco C; Cabas N; De Vita S; Beltrami AP; Curcio F; Quartuccio L
J Autoimmun; 2022 May; 129():102827. PubMed ID: 35427999
[TBL] [Abstract][Full Text] [Related]
17. Microfluidic antibody profiling after repeated SARS-CoV-2 vaccination links antibody affinity and concentration to impaired immunity and variant escape in patients on anti-CD20 therapy.
Priddey A; Chen-Xu MXH; Cooper DJ; MacMillan S; Meisl G; Xu CK; Hosmillo M; Goodfellow IG; Kollyfas R; Doffinger R; Bradley JR; Mohorianu II; Jones R; Knowles TPJ; Smith R; Kosmoliaptsis V
Front Immunol; 2023; 14():1296148. PubMed ID: 38259440
[TBL] [Abstract][Full Text] [Related]
18. Time Since Rituximab Treatment Is Essential for Developing a Humoral Response to COVID-19 mRNA Vaccines in Patients With Rheumatic Diseases.
Troldborg A; Thomsen MK; Bartels LE; Andersen JB; Vils SR; Mistegaard CE; Johannsen AD; Hermansen MF; Mikkelsen S; Erikstrup C; Hauge EM; Ammitzbøll C
J Rheumatol; 2022 Jun; 49(6):644-649. PubMed ID: 35232803
[TBL] [Abstract][Full Text] [Related]
19. The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study.
Christensen IE; Jyssum I; Tveter AT; Sexton J; Tran TT; Mjaaland S; Kro GB; Kvien TK; Warren DJ; Jahnsen J; Munthe LA; Haavardsholm EA; Vaage JT; Grødeland G; Lund-Johansen F; Jørgensen KK; Syversen SW; Goll GL; Provan SA
BMC Med; 2022 Oct; 20(1):378. PubMed ID: 36199139
[TBL] [Abstract][Full Text] [Related]
20. Persistent but atypical germinal center reaction among 3
Stefanski AL; Rincon-Arevalo H; Schrezenmeier E; Karberg K; Szelinski F; Ritter J; Chen Y; Meisel C; Jahrsdörfer B; Ludwig C; Schrezenmeier H; Lino AC; Dörner T
Front Immunol; 2022; 13():943476. PubMed ID: 36032111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]